Press Releases

Date	Title	View
November 13, 2024	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update	PDF Version
November 7, 2024	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference	PDF Version
September 28, 2024	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	PDF Version
September 18, 2024	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML	PDF Version
August 13, 2024	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update	PDF Version
May 29, 2024	Enliven Therapeutics to Present at Two Upcoming Investor Conferences	PDF Version
May 14, 2024	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update	PDF Version
April 11, 2024	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	PDF Version
April 9, 2024	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	PDF Version
March 28, 2024	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	PDF Version